Hong Kong Department of Health Approves Pemigatinib for Adults With FGFR2+ Locally Advanced/Metastatic Cholangiocarcinoma


Pemigatinib is a new treatment option following approval from the Hong Kong Department of Health for patients with locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement following progression on at least 1 prior line of therapy.

The Hong Kong Department of Health has approved the use of pemigatinib (Pemazyre) for adult patients with locally advanced or metastatic cholangiocarcinoma who have an FGFR2 fusion or rearrangement and have progressed following treatment with at least 1 previous line of therapy, according to a press release from Innovent Biologics.1

The indication was based on findings from the multicenter, open-label, single-arm phase 2 FIGHT-202 study (NCT02924376), which assessed pemigatinib at a dose of 13.5 mg in a population of patients with previously treated locally advanced/metastatic cholangiocarcinoma. Of the 108 patients with an FGFR2 fusion or rearrangement who were evaluable for response, investigators reported an overall response rate of 37.0% (95% CI, 27.94%-46.86%), with 4 patients achieving a complete response. Patients had a median duration of response of 8.08 months, with 66.0% of patients having a response lasting 6 months or more and 37.5% having a response lasting 12 months or more.

“The approval of [pemigatinib] in Hong Kong, following the approval in Taiwan earlier this year, further broadens Innovent’s product portfolio and market coverage. Currently, Innovent has developed a robust pipeline of 26 clinical assets and more than 80 projects in preclinical stage, along the way we have established strategic collaborations with a dozen of global and regional partners. We look forward to launching more innovative drugs to help fulfill unmet needs, overcome current therapeutic limitation and improve the life quality of patients,” Yongjun Liu, MD, PhD, president at Innovent Biologics, said in a press release.

Pemigatinib was approved by the FDA in April 2020 for the treatment of adult patients with pre-treated advanced FGFR2-positive cholangiocarcinoma.2 It was the first approved treatment aside from chemotherapy regimens for patients with FGFR2 fusion–positive or rearranged locally advanced/metastatic disease.


  1. Innovent announces the approval of Pemazyre (pemigatinib) in Hong Kong market for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or rearrangement that have progressed after at least one prior line Of systemic therapy. News release. Innovent Biologics. January 24, 2022. Accessed January 24, 2022. https://bit.ly/3Avjjs4
  2. FDA grants accelerated approval to pemigatinib for cholangiocarcinoma with an FGFR2 rearrangement or fusion. News release. FDA. April 17, 2020. Accessed January 24, 2022. https://bit.ly/3qUrjQ6
Related Videos
Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.
Future research into the management of unresectable hepatocellular carcinoma may involve combining local therapies with checkpoint inhibitors like durvalumab and tremelimumab, according to Ghassan K. Abou-Alda, MD.
Patients with unresectable hepatocellular carcinoma who have recurrent disease following surgery or locally advanced diseases who will likely progress on local therapy may have an opportunity to benefit from tremelimumab and durvalumab following its FDA approval, according to Ghassan K. Abou-Alfa, MD.
Ghassan K. Abou-Alfa, MD, discusses the importance of improving access to novel therapies and combinations for patients with hepatocellular carcinoma across the world.
Ghassan K. Abou-Alfa, MD, spoke about the recent approval of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma, based on results from the phase 3 HIMALAYA trial.
Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes (PRO)data that were presented at 2022 ASCO.
Shubham Pant, MD discusses key findings from a basket trial examining the use of erdafitinib in patients with gastrointestinal cancers.
Related Content